Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Benefit Exclusion

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy identifies medications, medication classes, products, and uses that are excluded from coverage by Neighborhood Health Plan of Rhode Island across Medicaid, Medicare, and Commercial lines of business.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyBenefit Exclusion
    Policy CodePolicy N/A
    Change TypeMaterial coverage update
    Effective DateOctober 6, 2026
    Last ReviewOct 6, 2026
    Next Review DateN/A
    Key ActionReview the member's line of business and confirm whether the medication or use falls within an expressly excluded category before submitting for coverage.
    SourceLink
    POLICY UPDATE CHANGES

    The Commercial benefit was updated to exclude medications used for weight loss.

    The Medicaid and Medicare lines of business were updated to exclude medications used solely for weight loss.

    The Medicaid benefit was updated to exclude medications such as puberty-blocking medications when prescribed for gender dysphoria (F64) in members under age 18.

    3Benefit categories addressed
    Not coveredPolicy stance

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    F64 under 18Medicaid gender dysphoria exclusion
    Weight lossWeight-loss exclusion

    Medication Benefit Exclusions

    The policy identifies medication categories, products, uses, and dispensing circumstances that are not covered under the applicable benefit. Exclusions vary by line of business and include items such as cosmetic, experimental, off-label, non-prescription, infertility, sexual or erectile dysfunction, medical marijuana, therapeutic or durable medical equipment products, and drugs lacking required FDA approval or support. Additional exclusions may apply to products dispensed outside plan requirements, obtained outside permitted pharmacies or locations, or otherwise covered under another benefit.

    Under the Medicaid benefit, medications prescribed for gender dysphoria (F64) in members under age 18 are excluded from coverage. This includes examples such as puberty-blocking medications.

    Under the Commercial benefit, medications used for weight loss are excluded. Under the Medicare benefit, drugs used to treat anorexia, weight loss, or weight gain are excluded. Some drugs in these categories may be coverable under the Medicaid portion of a FIDE benefit but are not payable under Medicare FIDE or CODE benefits; additionally, some weight-loss drugs may be covered under the Medicare benefit through the stated CMS Innovation Model pilot.

    Referenced Diagnosis Code

    Diagnosis code referenced in Medicaid exclusionICD-10
    F64Gender dysphoria

    Benefit-Specific Coverage Rules

    Denial Risk

    Medicaid Benefit Exclusions

    For the Medicaid benefit, the following products and uses are excluded and not covered. Verify the coverage basis before prescribing or dispensing, including FDA effectiveness, dispensing-guideline, and manufacturer rebate-program requirements.

    • Biological products for allergy immunizations and vaccinations.
    • Blood fractions.
    • Compound medications not made up of at least one legend drug.
    • Drugs prescribed or dispensed outside Health Plan dispensing guidelines.
    • Drugs not proven effective according to the FDA.
    • Drugs used for cosmetic purposes.
    • Drugs or products whose manufacturer does not participate in the Medicaid Drug Rebate Program (MDRP), meaning the manufacturer lacks a signed National Drug Rebate Agreement with the Secretary of HHS.
    • Experimental drugs, including drugs placed on notice of opportunity hearing status by the Federal Drug Efficacy Study Implementation (DESI).
    • Off-label drug use, unless mandated by laws pertaining to cancer treatment.
    • Medications used solely for weight loss.
    • Medications prescribed for gender dysphoria (F64) in members under age 18, including puberty-blocking medications.
    Denial Risk

    Commercial Benefit Exclusions

    For the Commercial benefit, do not consider excluded products or uses covered unless an expressly stated exception applies. Experimental use and off-label use are excluded, except when mandated by laws pertaining to cancer treatment; weight-loss medications are also excluded.

    • Any drug product used for cosmetic purposes.
    • Experimental drug products, off-label use of drug products, or any drug product used in an experimental manner, unless mandated by laws pertaining to cancer treatment.
    • Medications prescribed for sexual and/or erectile dysfunction (ED).
    • Medical marijuana.
    • Compounded products not made up of at least one legend drug.
    • Prescription and OTC homeopathic drugs.
    • Drugs lacking required FDA marketing approval, or whose approval has been withdrawn.
    • Medications used for weight loss.
    Denial Risk

    Medicare Benefit Exclusions

    For the Medicare benefit, exclude medications already covered under Medicare Part A or Part B and the other listed non-covered categories. Some drugs listed below may be coverable under the Medicaid portion of the FIDE benefit but are not payable by the Medicare FIDE or CODE benefits; some weight-loss drugs may be covered under the Medicare portion according to the GENEROUS pilot CMS Innovation model in mid-2026.

    • Medications that Medicare Part A or Medicare Part B already cover.
    • Medications used for sexual or erectile dysfunction.
    • Medications used to treat infertility.
    • Medications used for cosmetic purposes or to promote hair growth.
    • Medications made by a manufacturer that requires associated tests or monitoring services to be purchased only from that manufacturer as a condition of sale.
    • Medications used for indications that are not FDA-approved or compendia-supported, including off-label use.
    • Medications purchased outside the United States and its territories.
    • Non-prescription drugs; drugs for symptomatic relief of cough or cold symptoms; prescription vitamins and mineral products, except prenatal vitamins and fluoride preparations; and drugs used to treat anorexia, weight loss, or weight gain.
    • Medications used solely for weight loss.
    • Some drugs in these excluded categories may be coverable under the Medicaid portion of the FIDE benefit but are not payable by the Medicare FIDE or CODE benefits.
    • Some weight-loss drugs may be covered under the Medicare portion of the benefit according to the GENEROUS pilot CMS Innovation model in mid-2026.

    Policy Context

    This is an administrative benefit-exclusion policy, not a medical-necessity guideline. Coverage depends on the member's line of business and applicable benefit, as well as factors such as the product's regulatory status, approved or supported indication, dispensing circumstances, and whether the item falls within an expressly excluded category.

    Terms and Abbreviations

    F64
    CodeF64
    DescriptionGender dysphoria
    Policy relevanceMedications prescribed for gender dysphoria (F64) are excluded under the Medicaid benefit for members under age 18.
    Medicaid Drug Rebate Program (MDRP)
    AcronymMDRP
    DefinitionThe Medicaid Drug Rebate Program.
    Policy relevanceMedicaid excludes drugs or products whose manufacturer does not participate in MDRP—that is, the manufacturer does not have a signed National Drug Rebate Agreement on file with the Secretary of the Department of Health and Human Services.
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyBenefit Exclusion
    Policy CodePolicy N/A
    Change TypeMaterial coverage update
    Effective DateOctober 6, 2026
    Last ReviewOct 6, 2026
    Next Review DateN/A
    Key ActionReview the member's line of business and confirm whether the medication or use falls within an expressly excluded category before submitting for coverage.
    SourceLink
    On This Page
    Medication Benefit ExclusionsReferenced Diagnosis CodeBenefit-Specific Coverage RulesPolicy ContextTerms and Abbreviations
    Drug Efficacy Study Implementation (DESI)
    AcronymDESI
    DefinitionThe Federal Drug Efficacy Study Implementation.
    Policy relevanceMedicaid excludes experimental drugs, including drugs placed on notice of opportunity hearing status under DESI.